A little suprised at how well advanced the Conneqt band is. Personally did not put much emphasis to the success of this. A few statements below from the release.
"We are currently preparing the CONNEQT Band and its associated
mobile application for the final NIH RADx® prize round in November 2023"
"This means that our SphygmoCor technology can also be applied to finger-based and wearable devices such as pulse oximeters and mass market fitness trackers"
"21 participants, demonstrating clinical reliability of our ground-breaking device"
"The results have been extremely encouraging, consistently yielding
reliable results when compared to a tonometer-based approach, which is the “gold standard” for
arterial health assessments."
Great update and why i invested in this company.
But still one issue still not addressed.
CDX Price at posting:
13.5¢ Sentiment: Hold Disclosure: Held
